4D Molecular Therapeutics (FDMT) Common Equity (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Common Equity data on file, last reported at $451.8 million in Q1 2026.

• On a quarterly basis, Common Equity fell 3.81% year-over-year to $451.8 million in Q1 2026; TTM through Mar 2026 was $451.8 million, a 3.81% decrease from a year earlier, with the FY2025 full-year figure at $505.7 million, down 0.97% from the prior year.
• Common Equity for Q1 2026 stood at $451.8 million, down from $505.7 million in the prior quarter.
• Over the last five years, Common Equity for FDMT reached as high as $600.6 million in Q1 2024 and fell as low as $218.6 million in Q1 2023.
• Historically, Common Equity has averaged $394.3 million across 5 years, with a median of $369.0 million in 2025.
• Across the five-year window, Common Equity jumped 174.72% in 2024 and plunged 33.27% in 2025, its largest moves.
• Year by year, Common Equity stood at $231.3 million in 2022, then surged by 33.07% to $307.8 million in 2023, then soared by 65.87% to $510.6 million in 2024, then retreated by 0.97% to $505.7 million in 2025, then dropped by 10.65% to $451.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $451.8 million in Q1 2026, $505.7 million in Q4 2025, and $369.0 million in Q3 2025.